文献速递炎症性肠病

英夫利西单抗与维得利珠单抗在生物制剂初治溃疡性结肠炎中的疗效比较

Comparative Efficacy for Infliximab Vs Vedolizumab in Biologic Naive Ulcerative Colitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-07-28

该事后分析基于3项临床试验项目中795例生物制剂初治的中重度溃疡性结肠炎患者,比较英夫利西单抗与维得利珠单抗的疗效。第6周临床缓解和应答比例两组相当,但英夫利西单抗1年内镜缓解和免激素临床缓解率显著更高。

要点

  • 第6周临床应答与缓解率英夫利西单抗与维得利珠单抗相当。
  • 英夫利西单抗1年内镜缓解率显著高于维得利珠单抗。
  • 英夫利西单抗1年免激素临床缓解率显著更高。

核心结论

  • 英夫利西单抗与维得利珠单抗在改善临床症状方面疗效相似,但英夫利西单抗在生物制剂初治溃疡性结肠炎中1年免激素临床缓解率和内镜缓解率更高。

研究设计与样本

  • 事后分析,纳入3项溃疡性结肠炎临床试验项目中共795例生物制剂初治患者,采用多变量logistic回归调整混杂因素,并进行倾向性评分匹配敏感性分析,所有分析均为意向性治疗。

主要发现

  • 1年临床缓解率英夫利西单抗组为39.9%(91/228),维得利珠单抗组为38.6%(219/567),调整OR=1.02,95%CI 0.74-1.40。
  • 1年内镜缓解率英夫利西单抗组为36.0%(82/228),维得利珠单抗组为25.6%(145/567),调整OR=1.60,95%CI 1.12-2.28。
  • 1年免激素临床缓解率英夫利西单抗组为29.5%(23/78),维得利珠单抗组为15.0%(38/254),调整OR=2.36,95%CI 1.27-4.39。

关键数值与推荐

  • 1年临床缓解:英夫利西单抗39.9% vs 维得利珠单抗38.6%(调整OR=1.02,95%CI 0.74-1.40)。
  • 1年内镜缓解:英夫利西单抗36.0% vs 维得利珠单抗25.6%(调整OR=1.60,95%CI 1.12-2.28)。
  • 1年免激素临床缓解:英夫利西单抗29.5% vs 维得利珠单抗15.0%(调整OR=2.36,95%CI 1.27-4.39)。

临床怎么用

  • 对于生物制剂初治的中重度溃疡性结肠炎患者,若优先考虑1年内镜缓解和免激素缓解,英夫利西单抗可能更具优势。
  • 若关注短期临床症状改善,英夫利西单抗与维得利珠单抗疗效相当,选择需结合患者具体情况。

局限性

  • 本研究为事后分析,非头对头随机对照试验,可能存在未测量的混杂因素。
  • 数据来源于临床试验项目,患者特征和临床实践可能与真实世界存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Comparative effectiveness studies are needed to help position therapies for ulcerative colitis (UC). We compared the efficacy of infliximab vs vedolizumab for moderate to severe biologic-naïve UC using patient-level data from clinical trial program data sets. METHODS: This was a post hoc analysis of 3 UC clinical trial programs that included data on 795 biologic-naïve UC patients. Differences in proportions of patients achieving week 6 clinical remission (CR) and response, and 1-year CR, corticosteroid-free CR, and endoscopic remission (ER), are reported. Multivariate logistic regression was used to adjust for potential confounders. As a sensitivity analysis, propensity scores were calculated and a cohort of matched participants with similar distribution of baseline covariates was created. All analyses were intention-to-treat. RESULTS: At week 6, comparable proportions of patients achieved clinical response and CR with infliximab vs vedolizumab (clinical response, 60.5% [138 of 228] vs 60.0% [340 of 567]; P = .884; and CR, 39.9% [91 of 228] vs 38.6% [219 of 567]; P = .736). Similar proportions of patients achieved 1-year CR with infliximab vs vedolizumab (39.9% [91 of 228] vs 38.6% [219 of 567]; adjusted odds ratio [aOR], 1.02; 95% CI, 0.74-1.40). Infliximab-treated patients had significantly higher rates of 1-year ER (36.0% [82 of 228] vs 25.6% [145 of 567]; aOR, 1.60; 95% CI, 1.12-2.28) and corticosteroid-free CR (29.5% [23 of 78] vs 15.0% [38 of 254]; aOR, 2.36; 95% CI, 1.27-4.39). Similar results were observed in the propensity score matched cohort. CONCLUSIONS: Although infliximab and vedolizumab have similar efficacy in clinical symptom improvement, infliximab had higher rates of 1-year corticosteroid-free CR and ER in treatment of biologic-naïve UC.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Narula N, Wong ECL, Marshall JK, et al. Comparative Efficacy for Infliximab Vs Vedolizumab in Biologic Naive Ulcerative Colitis. Clin Gastroenterol Hepatol. 2021. PMID: 34329776. doi:10.1016/j.cgh.2021.07.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。